Trials / Completed
CompletedNCT02835664
Nicotinamide Riboside and Metabolic Health
Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Maastricht University Medical Center · Academic / Other
- Sex
- All
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the effects of 6 week Nicotinamide Riboside supplementation (1000 mg/day) on metabolic health in healthy (pre)obese humans. The primary objective will be hepatic and whole body insulin sensitivity. Secondary objectives, to provide information about the underlying mechanism, will be muscle mitochondrial function, brown fat activity, ectopic lipid accumulation, energy metabolism, cardiovascular risk parameters, body composition and acetylcarnitine levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Nicotinamide Riboside (Niagen) | |
| DIETARY_SUPPLEMENT | Placebo |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2016-07-18
- Last updated
- 2019-03-22
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02835664. Inclusion in this directory is not an endorsement.